Oliver Fiehn Joins Luventix Advisory Board
Luventix, a leading innovator in Intelligent Disease Diagnostics, is proud to announce that Dr. Oliver Fiehn, a distinguished expert in metabolomics and systems biology, has joined its Advisory Board.
Dr. Fiehn, a professor and prominent researcher at the University of California, Davis, brings decades of experience in advancing analytical and computational approaches in metabolomics. With an extensive background in integrating cutting-edge technologies into real-world applications, his insights will play a pivotal role in guiding Luventix's growth and innovation strategies.
"We are thrilled to welcome Oliver Fiehn to our Advisory Board," said George Holmes, CEO of Luventix. "His deep expertise and forward-thinking perspective align perfectly with our mission to drive down the cost of healthcare by making low cost diagnostics solutions available to all!"
Dr. Fiehn's addition strengthens Luventix's commitment to excellence and innovation as it continues to pioneer solutions in urine based diagnostics.
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com
Media Contact:
